Search

everythinglearnresearchcommunity

for

Search:↓

A woman with alopecia universalis shares her positive experience of being bald, finding it freeing and less worrisome. She also discusses her skincare routine using Korean products.

A 27-year-old male with androgenetic alopecia has been using finasteride, topical minoxidil, and microneedling for over six months to stabilize hair loss and prepare for a potential hair transplant. While some users suggest switching to dutasteride and increasing minoxidil usage, others note minimal progress, with some hair stabilization but concerns about thinning at the crown.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A 20-year-old woman with androgenetic alopecia feels depressed about her hair loss, despite using topical minoxidil, spironolactone, and saw palmetto. Suggestions include trying oral minoxidil, higher doses of finasteride or dutasteride, and checking for vitamin deficiencies and heavy metal exposure.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

Diffuse thinning is often due to androgenetic alopecia, and DHT blockers like finasteride are recommended. Treatments mentioned include minoxidil, finasteride, dutasteride, and RU58841, with emphasis on starting early and using a holistic approach.

A 30-year-old male with androgenic alopecia shows progress after using dutasteride (0.5 mg daily) and topical minoxidil (5% twice daily) for 3.5 months. Users suggest adding dermastamping for better results.

A 25-year-old woman with androgenic alopecia is experiencing hair dryness and damage after using topical minoxidil and Nizoral. She is advised to reduce washing frequency, use a bond builder like K18, apply a silicone-based serum, and consider using a shower filter and different oils like argan oil for better hair health.

A user with aggressive androgenic alopecia is considering increasing their dutasteride dose from 0.5 mg to potentially 2.5 mg, while already using oral minoxidil, Nizoral, RU-58841, and dermapen. They are seeking advice on the effectiveness and side effects of higher dutasteride doses, with suggestions to consult a dermatologist and consider a higher Nizoral concentration.

A 36-year-old man with androgenetic alopecia suspects copper and zinc deficiencies may be accelerating hair loss and is supplementing copper to address this. He is also monitoring blood sugar levels due to previous prediabetes concerns and plans to test for insulin resistance.

A 26-year-old man with diffuse alopecia is using electric scalp massage, dermastamp, and multivitamins for treatment but is intolerant to finasteride. A dermatologist recommended PRP and mesotherapy with exosomes and dutasteride.

A user with seborrheic dermatitis and traction alopecia is seeking alternatives to minoxidil for hair loss, considering rosemary oil for its anti-inflammatory properties. They express concerns about potential side effects and effectiveness of various treatments, including rosemary oil, caffeine, and Redensyl.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user is concerned about potential alopecia areata. They are seeking advice on whether this condition is normal.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

A 29-year-old male with androgenic alopecia was treated with oral Dutasteride, oral Minoxidil, and injectable Dutasteride, showing progress in 9 months. Some users believe Dutasteride mesotherapy is unnecessary and question its effectiveness compared to topical applications.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

A user is asking women with androgenic alopecia about the effective dose of spironolactone for hair regrowth, mentioning they've been on 100 mg for a year with minimal results and considering increasing the dose. The conversation focuses on the effectiveness of spironolactone for hair loss treatment.

A user is experiencing androgenic alopecia and is considering using Vichy's aminexil for hair regrowth. They seek advice on its effectiveness and whether to combine it with microneedling.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

A 24-year-old male with androgenetic alopecia is using a treatment of Dutasteride 0.5 mg, oral Minoxidil 2.5 mg, L-cysteine, and a Ketoconazole/Caffeine/CBD shampoo. He's considering using a dermaroller to improve results, taking biotin and iron vitamins, and quitting nicotine due to its potential link to hair loss.

A person treated their diffuse alopecia with oral minoxidil (10mg daily), oral finasteride (reduced to 0.25mg daily due to side effects), castor oil, vitamins, and ashwagandha, and plans a hair transplant in Turkey. They stopped using topical minoxidil, have seen improved hair density, but are still experiencing hair loss.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

A 50-year-old Black woman with alopecia areata and traction alopecia is seeking a science-based hair loss routine. Current treatments include spearmint tea for DHT levels and considering PRP.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.